What’s the matter with wages? With strong hiring, workers should be getting higher pay — but they aren’tWorkers are in high demand, so they should be commanding top dollar. Caroline Baum explores why they aren’t getting big raises.

Romaine lettuce is the culprit in E. coli outbreak sickening people in at least 11 statesThe Centers for Disease Control and Prevention has identified romaine lettuce grown around Yuma, Ariz., as the cause of an E. coli outbreak that has sent 22 people to the hospital and made 13 more sick.

Tammy Duckworth, 50, is first sitting U.S. Senator to give birth while in office Fortysomething women are reversing a 40-year trend for new motherhoodFortysomething women are reversing a 40-year trend for new motherhood..

Good news for Super Bowl viewing — no more ads for toenail-fungus drugs This could be the second year in a row without pharmaceutical Super Bowl commercialsRemember the anthropomorphic, helmeted foot hustling across a football field to ‘tackle’ toenail fungus?

FTSE 100 erases 2018 gain as U.S. bond selloff spooks investors Pound briefly dips below $1.40U.K. stocks dropped for the first time in three days on Tuesday, tracking a selloff in the U.S. and Asia that came as investors got nervous about a rally in U.S. bond yields.

Gene therapy stocks tank after leading scientist reveals safety concerns; Solid Bioscience down 15%Shares of gene therapy companies fell sharply Tuesday, after a report by a prominent scientist revealed the safety concerns that led him to resign recently from Solid Bioscience Inc.'s scientific advisory board. Gene therapy researcher James Wilson, a giant in the field, quit the board ahead of its IPO because of the possible risks of high systemic dosing of AAV, the company's delivery system, according to the company's IPO prospectus. Just hours before Solid Bioscience priced its IPO last week, it revealed that the U.S. Food and Drug Administration had placed a partial clinical hold on the company's lead product, SGT-001, a treatment for Duchenne muscular syndrome that involves high-dose AAV gene therapy. On Monday, Wilson and his team published a paper that revealed that monkeys and pigs used in an animal trial were sent into toxic crisis when given a high dose AAV delivery of a corrective gene. Solid Bioscience shares led the decliners, sliding 16%, AveXis Inc. shares were down 10% and Audentes Therapeutics Inc. shares slid about 4%. The S&P 500 was down 0.9%.

What Jeff Sessions doesn’t understand about medical marijuana The research on medical marijuana is clear: Marijuana has legitimate medical usesThe Rohrabacher–Farr amendment that bars the Justice Department from spending money to keep states from implementing their own laws about “the use, distribution, possession or cultivation of medical marijuana” expires on Jan. 18.

GW Pharma's cannabis-derived drug to be reviewed by FDA GW Pharmaceuticals plc said early Thursday that the Food and Drug Administration will review a new drug application for its cannabis-derived drug epidiolex for seizures associated with two rare types of childhood epilepsy. The application was accepted for priority review, a special status that offers an accelerated review for high-priority products, and the regulator aims to have a decision by or on June 27, 2018. If approved, epidiolex -- which contains cannabidiol (CBD), rather than the psychoactive component of cannabis, THC -- could be the country's first cannabis-derived drug. (link: https://www.marketwatch.com/story/zynerba-pharmas-failed-cannabidiol-gel-trial-has-upside-for-rival-gw-pharma-2017-08-07) That the product is derived from cannabis will likely be the focus of debate among investors in the coming months and of an FDA advisory committee meeting reviewing the product, expected around April or May, said Leerink Partners analyst Paul Matteis. "A hypothetical positive vote from a panel of physicians can help prevent a problematic media narrative that Epidiolex is 'marijuana for kids' and instead can cultivate a more accurate narrative that Epidiolex represents an important, generally safe medicine for children with serious, sometimes fatal epileptics," Matteis, who rates the company outperform, said. "It's possible that the FDA may also ask questions around medical marijuana use in epilepsy today, and how physicians are considering that the approval of Epidiolex could increase this dynamic by lending credence to cannabis itself being an effective anti-convulsant." He expects the drug will be approved and have a "very strong launch," given three positive late-stage trials; "favorable reimbursement dynamics in epilepsy + high patient awareness/demand will represent tailwinds for a successful launch: we assume $1.5B in gross 2025 sales," he added. Epidiolex's Thursday filing was for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome; the therapy is also being developed for tuberous sclerosis complex and infantile spasms. Shares were down 2% Thursday, but have gained 19.5% in 2017, while the S&P 500 has gained 20%.

Diet soda isn’t good for you: Why this doctor is swearing them off The long-term effects of diet sweeteners is unknownDrinks and foods marketed to help us maintain weight may have been helping us to gain it.

Michelle Obama didn’t mention Trump’s name — because she didn’t need toIn 1978, a pair of clinical psychologists came up with a phrase to describe somebody who feels the need to keep reminding us of how great they are, while clearly struggling with feelings of inadequacy on the inside. Anybody come to mind?

Omm, my God! Christian yoga causes an uproar Some adaptations include swapping out Buddha statues for hardcover BiblesThere are thousands of Christian yoga instructors plying their trade around the world and they’ve had to make the centuries-old practice gel better with their belief system.

6 ways you may be sabotaging your relationship — with your investments Holding on too long, being stubborn, setting the wrong priorities and moreHolding on too long, being stubborn and setting the wrong priorities: Just like in a personal relationship, unlearning behavior you’ve been doing for years, if not decades, takes work.

3 arguments for not touching your 401(k) in early retirement The idea that people spend less in retirement is absurd. Here’s what to do about it The idea that people spend less in retirement is absurd. Here’s what to do about it.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.